An observational study in Atrial Fibrillation and Gerontology, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Completed at 5 sites in France. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2017-01-23.
Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational
Atrial fibrillation (AF) is a rhythmic cardiac activity disorder disturbing hemodynamic blood flow. It is a public health problem with 600,000 to 1 million people involved in France which 2/3 are aged over 75 years. a FA untreated exposes the patient to a significant risk of embolism responsible for a rate stroke (stroke) ischemic estimated at 85%. The anticoagulant standard treatment helps prevent the occurrence of this complication.
However, oral anticoagulation also exposes patients to an increased risk of bleeding. The bleeding risk can be assessed using scales: several being proposed (HEMORR2HAGES, HAS-BLED, ATRIA and scores Shireman and Charlson ...).
moreover, in geriatric hospital care, every patient has a "standardized geriatric assessment" to assess and quantify functional capacity, autonomy, cognitive abilities, nutritional status, psychological state and its environment social.
Thus, the objective of the investigators study was to determine the frequency of each item of each bleeding risk assessment score and geriatric assessment in patients 80 and older hospitalized geriatric ward in the department and with anticoagulant.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's enrollment of 120 is below the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 578 studies on the registry; 128 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients seniors with atrial fibrillation with anticoagulant treatment
Exclusion Criteria:
Other: questionnaires
scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
scale : HEMORR2HAGES
hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...
Time frame: at baseline
scale : HAS-Bled
arterial hypertension, renal function, liver function, cerebrovascular accident...
Time frame: at baseline
scale : ATRIA
anemia, serious kidney diseases, hypertension, antecedent...
Time frame: at baseline
scale : shireman
gender, age, hemorrhage, diabetes, anemia...
Time frame: at baseline
scale charlson
age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer
Time frame: at baseline
scale : standardised geriatric assessment
comorbidities, cognition, mobility, pain, nutrition, living environment...
Time frame: at baseline
Occurrence of major bleeding event or not major
Time frame: at baseline and 6 months
genotyping
CYP2C9
Time frame: at baseline
genotyping
VKCRC1
Time frame: at baseline
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Saint Etienne